-
Your prediction
Pros and Cons of TC BioPharm Holdings plc ADR in the next few years
Pros
Cons
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Diving into the financials of TC BioPharm, it's notable that the company presents several key indicators that garner attention. With a modest Market Capitalization of $5.0095 million, it sits in the bracket of micro-cap companies, which often means it could have high growth potential but also higher volatility and risk. A striking figure is the negative EBITDA at around -$10.98 million, indicating that the company is currently not profitable at an operating level. This is further underscored by the absence of a P/E ratio and the heavy negative earnings per share (EPS) of -$3.25, showing that the company is experiencing significant losses in relation to its share price.
In terms of valuation metrics, the company currently has a Trailing Price to Earnings (P/E) ratio of 0 and a Forward P/E of 0, which signifies that the company is not generating positive earnings, making traditional earnings-based valuation metrics inapplicable. While the company does generate revenue, with a trailing twelve months (TTM) figure of $2,855,202, the valuation ratios based on sales and book value are not provided, suggesting that these may not present an attractive picture either.
Detailed Analysis